


ANGELMAN SYNDROME

Vanessa Gallegos

ANGELMAN SYNDROME

CLASSICAL DIAGNOSIS



In 1965, Dr. Harry Angelman first described the characteristics that later became known as Angelman Syndrome.

It was considered to be extremely rare, until the 1980s when North American reports began to appear.

Now it is estimated between 1 in 12,000 to 20,000 people.

WHAT CAUSES ANGELMAN SYNDROME

Loss of function of a gene called UBE3A.

Deletion- 70%

a segment of the maternal chromosome 15 is deleted.

Mutation- 11%

in the maternal copy of UBE3A.

Paternal Uniparental Disomy- Small number

2 paternal copies of chromosome 15 are inherited

Translocation- Rarely occurs

a mutation or other defect occurs in the area of DNA responsible for activation of the *UBE3A*.

The causes in 10-15% of the cases are unknown.


TREATMENT

Symptomatic treatments involve:

- Antiepileptic Drugs (seizures)
- Stimulants (hyperactivity)
- Diphenylhydramines (nighttime wakefulness) Thorco-lumbar jackets (scoliosis)
- Surgery (orthopedic and other physical problems)
- Educational Training
- **Physical Therapy**
- There are currently no <u>preventative</u> treatments for Angelman Syndrome.

THE TRIALS

Clinical trials are attempting to augment **DNA** methylation pathways and increase the expression of the paternal UBE3A, however, initial trials did not show significant clinical benefit.



THE FUTURE

- A possible breakthrough using topoisomerase inhibitors to un-silence the *UBE3A* gene.
- The research examined more than 2,000 drugs to un-silence the paternal gene in mice.

SYNDROME FOUNDATION, INC.®

REFERENCES

http://www.angelman.org/stay-informed/facts-about-angelm http://beaconnews.suntimes.com/news/9935048-418/aurora http://ghr.nlm.nih.gov/condition/angelman-syndrome